Cheban Alexey V, Osipova Olesya S, Ignatenko Pavel V, Gostev Alexandr A, Saaya Shoraan B, Karpenko Andrey A
Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russia.
Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russia -
Int Angiol. 2025 Apr;44(2):150-158. doi: 10.23736/S0392-9590.25.05272-1.
The present study investigates the hypothesis that fasciotomy of the Hunter's canal increases the mobility of the superficial femoral artery and reduces the risk of stent fracture. The objective of this study was to compare the long-term success of drug-eluting nitinol stents with and without a fasciotomy for patients with total femoropopliteal occlusion. The hypothesis is that fasciotomy of Hunter's canal can increase the mobility of the superficial femoral artery and reduce the incidence of stent breakage. The objective of this study was to compare the long-term patency of drug-eluting nitinol stents with and without fasciotomy in patients with total femoropopliteal occlusions.
A randomized clinical trial was conducted in patients with femoral-popliteal stenococclusive lesions longer than 200 mm. Patients in group 1 (Zilver) underwent recanalization of the femoropopliteal artery occlusion with stenting. In the second group (ZilverFas), recanalization of the femoropopliteal occlusion with stenting and fasciotomy of Hunter's canal was performed. The follow-up evaluation of patency was conducted at 24 months.
The present study involved a total of 60 subjects. The primary patency at 24 months was 33% and 60% in the Zilver and ZilverFas groups, respectively (P=0.03). The freedom from target revascularization (TLR) in the Zilver and ZilverFas groups was 40% and 64%, respectively (P=0.1). The primary assisted patency at 24 months was 46.7% in the Zilver group versus 66.5% in the ZilverFas group (log-rank P=0.14) versus 46.7% in the Zilver group (log-rank P=0.14), while the 2-year secondary patency was 53.3% in the Zilver group compared to 69% in the ZilverFas group (log-rank P=0.24) compared to 53.3% in the Zilver group (log-rank P=0.24). In the Zilver and ZilverFas groups, the number of patients with stent failures was 14 and 7, respectively (P=0.05). In the Zilver and ZilverFas groups, the number of stents that fractured was 14 and 7, respectively (P=0.05). Multivariable Cox regression analysis revealed that fasciotomy significantly reduced the risk of reocclusion and restenosis by 2.1 times.
The present study has demonstrated that decompression of the stented segment of the superficial femoral artery (SFA) with fasciotomy leads to a significant improvement in patency of the femoropopliteal segment and a substantial reduction in the number and severity of stent fractures.
本研究探讨如下假说:亨特氏管筋膜切开术可增加股浅动脉的活动性并降低支架断裂风险。本研究的目的是比较药物洗脱镍钛合金支架置入术联合或不联合亨特氏管筋膜切开术治疗股腘动脉完全闭塞患者的长期成功率。假说为亨特氏管筋膜切开术可增加股浅动脉的活动性并降低支架断裂发生率。本研究的目的是比较药物洗脱镍钛合金支架置入术联合或不联合筋膜切开术治疗股腘动脉完全闭塞患者的长期通畅率。
对股腘动脉狭窄闭塞性病变长度超过200 mm的患者进行一项随机临床试验。第1组(Zilver组)患者接受股腘动脉闭塞再通并置入支架。第2组(ZilverFas组)患者接受股腘动脉闭塞再通、置入支架及亨特氏管筋膜切开术。在24个月时进行通畅情况的随访评估。
本研究共纳入60名受试者。Zilver组和ZilverFas组24个月时的主要通畅率分别为33%和60%(P = 0.03)。Zilver组和ZilverFas组免于靶血管再通(TLR)的比例分别为40%和64%(P = 0.1)。Zilver组24个月时的主要辅助通畅率为46.7%,而ZilverFas组为66.5%(对数秩检验P = 0.14);Zilver组2年的次要通畅率为53.3%,而ZilverFas组为69%(对数秩检验P = 0.24)。在Zilver组和ZilverFas组中,支架失败的患者数量分别为14例和7例(P = 0.05)。在Zilver组和ZilverFas组中,发生断裂的支架数量分别为14个和7个(P = 0.05)。多变量Cox回归分析显示,筋膜切开术使再闭塞和再狭窄风险显著降低2.1倍。
本研究表明,采用筋膜切开术对股浅动脉(SFA)支架置入段进行减压可显著改善股腘段的通畅情况,并大幅减少支架断裂的数量和严重程度。